Research graph

References

References from Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes. Local targets link to admitted publications; unresolved targets remain external evidence.